Companies That Sell Molecular Enzyme Analyses
Numerous companies are selling molecular enzymes. ArcticZymes, Thermo Fisher Scientific, QIAGEN, and Illumina are among the leading companies in the market. Detailed analysis is also available, including regional and COVID-19 analyses. For more information, contact one of the companies listed below. We will discuss the benefits of using these companies’ products and how to choose the best option for your application.
ArcticZymes is a company that manufactures and sells molecular enzymes. Its products are used in many different diagnostic tests, including those for the COVID-19 virus. Cod UNG is one such enzyme, but developers of COVID-19 diagnostic tests have expressed a desire for other types of enzyme components, including high-grade DNA polymerases and reverse transcriptases. These enzymes are key components of PCR, LAMP, and other amplification techniques. ArcticZymes hopes to drive innovation for COVID-19 diagnostic tests.
The company has two separate divisions. One is based in Norway and is owned by Biotec. The other operates under the AZT ticker. In the third quarter of this year, the company sold NOK 30.8 million of its products and generated an EBITDA of NOK 10.1 million. Both of these companies have a history of growth and are positioned to continue to deliver profitability. The company recently hired Brent Spoth, a Ph.D. in microbiology from Virginia.
Another division works with biotechnology companies. The company has developed its molecular enzyme. ArcticZymes Proteinase is a novel heat-labile enzyme. It is inactivated after use, allowing more compatible products to be created. ArcticZymes has worked with collaborators and customers to demonstrate the benefits of this enzyme. They have worked with Associate Professor Anders Stahlberg, a leading authority in single-cell biology and liquid biopsies. Using the enzyme in this way, he has demonstrated that it effectively overcomes challenges in isolating low-abundance DNA samples.
ArcticZymes Technologies ASA manufactures and sells novel recombinant enzymes as a biotechnology company. Its products include Woulgan wound gel, Feed Ingredient (M-Glucan), and Nutraceuticals (M-Gard). The company reports to the Enzymes and Corporate sections and generates most of its revenue in the United States. Further, the company has two subsidiaries that develop and market beta-glucans, immune-modulating compounds, and anti-inflammatory drugs.
AZT was previously known as Biotec Pharmacon. During its evolution, the company launched Woulgan, a wound-healing product. Unfortunately, it failed to gain commercial traction and was sold for 70 million NOK in 2020. After that, the company renamed itself ArcticZymes Technologies and focused its resources on the enzyme business. The company’s product line and production capacity expanded significantly, and Jethro Holter is now the new CEO.
To gain access to a larger market, Thermo Fisher is expanding its portfolio of products. In December 2010, the company announced that it had acquired Dionex for $2.1 billion. The acquisition will provide TMO with a broad range of products in the diagnostics and biotechnology sectors. The acquisition is expected to provide the company with new revenue streams and enhance its existing diagnostics business. However, it is unclear whether the deal will benefit customers.
The company said that the deal would increase its portfolio of products for polymerase chain reactions. In addition, it plans to integrate Fermentas into its analytical technologies division. Fermentas, which has 500 employees, is based in Waltham, Mass. Thermo Fisher said it intends to integrate Fermentas into its current business. Combined with their existing products, the two companies will be able to provide a greater variety of research tools for scientists.
Fermentas will provide high-quality molecular research tools, including restriction enzymes, modifying and purification reagents, and molecular weight markers. Fermentas also produces various PCR products and will join Thermo Fisher’s portfolio of reagents and kits for this use. The transaction is expected to close in the third quarter of 2010, and it will have no material effect on financial results.
Oncomine solid tumor DNA kit, CE-IVD Oncomine oncology solid tumor DNA, is a versatile product from Thermo Fisher Scientific. This kit allows for accurate multiplex sequencing of formalin-fixed paraffin-embedded tumor DNA using Ion Torrent AmpliSeq technology. Thermo Fisher sells molecular enzymes, reagents, and other tools to conduct high-quality genomic analysis.
Companies that produce molecular enzymes are often required to comply with REACH regulations. This European Union regulation covers Life Science companies selling their products in Europe. It aims to control the use of substances of very great concern. Detergents such as phosphatidylcholine, commonly used in the molecular biology industry, are included in the substances subject to high regulation. To ensure compliance with the regulation, QIAGEN, and its OEM partners are making their products compliant with REACH.
In addition, QIAGEN has signed agreements to acquire a majority of Blirt, a Gdansk, Poland-based manufacturer of recombinant enzymes for the life sciences industry. The company’s products are critical to the life sciences industry, as well as for non-COVID-19 applications. According to its most recent quarterly financial results, Blirt had total revenue of less than $10 million in 2014, and QIAGEN expects to achieve this goal in the next two years.
The acquisition of Enzymatic provides QIAGEN with deep capabilities in enzyme formulation, R&D, and analytical capabilities. The company will continue developing and commercializing its products through QIAGEN, enabling the broad adoption of genetic analysis technologies. As a result, the two companies are now offering a complete NGS workflow. This partnership is another key element of QIAGEN’s NGS strategy and will strengthen the company’s universal NGS products.
In addition to its comprehensive test panels, QIAGEN has extensive capabilities in oncology. It has become the leader in screening for high-risk HPV. Additionally, the company offers tests for food safety pathogens, genetically modified organisms, and origins. Moreover, QIAGEN also offers a range of forensic tests and pandemic prevention and monitoring. Further, the company provides services to the healthcare industry, including hospitals, pharmaceutical companies, and research institutions.
The global molecular enzyme market is segmented into four main regions: North America, Europe, Asia Pacific, and RoW. North America will hold the largest share of the market by 2020. The Asia Pacific and Europe will follow. China has become one of the largest investors in R&D and is projected to overtake the US in 2023. As a result, many companies have expanded operations in China.
Companies like Illumina and Ambry have developed advanced sequencing technologies to pinpoint the causes of diseases. Scientists at Illumina sell their tools to clinicians and researchers. Most of these companies take on compelling cases, like those of children with debilitating symptoms and no current diagnosis. Illumina also offers employee benefits like free screening tests. While the company may seem expensive, it has a high-profit margin.
The companies behind Illumina and other companies that sell molecular enzymes have several challenges. They need to continue to innovate while maintaining their grip on their core business. Illumina has recently announced several new “moonshot” ventures, including the Grail, a $100 million venture that aims to bring early cancer screening to every doctor’s office. Another recent move to strengthen its leadership team is the addition of former Apple executive Phil Schiller to its board. Schiller has a strong background in consumer marketing, which could help Illumina better serve its customers.
Another potential competitor to Illumina is Oxford Nanopore. The company provides services and hardware for the sequencing market. However, Oxford Nanopore settled with Illumina in August. Despite the differences, the future of Illumina and Oxford Nanopore is bright. If the Oxford Nanopore partnership doesn’t work out, Illumina’s product may not be available. It is unclear whether or not the companies will continue to cooperate.